NSE: ALKEM · 12 November 2026
- Alkem Laboratories Ltd. (ALKEM) declined by 2.68% on Wednesday, closing at ₹5,302.0 after moving within a wide intraday range between a low of ₹5,173.0 and a high of ₹5,422.0.
- Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named 'Alkem Pharma Company' as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.
- Trading volume was 9.44 times the 20-day average daily volume.
Why is Alkem Laboratories share price falling on 12 November 2026?
Alkem Laboratories Ltd. (ALKEM) declined by 2.68% on Wednesday, closing at ₹5,302.0 after moving within a wide intraday range between a low of ₹5,173.0 and a high of ₹5,422.0.
The broader market showed modest positive momentum, with the benchmark Nifty index rising by 0.18%, whereas the Nifty Pharma sector index edged down by 0.35%. Alkem's decline outpaced the sectoral softness, contrasting with its recent multi-day performance that included a 5-day return of 1.64% and a 20-day return of 0.99%.
Company filings provided fresh context following the announcement of its standalone and consolidated financial results for the quarter ended September 30, 2026. Alkem reported a 13.8% year-on-year growth in total revenue from operations at ₹45,520 million, supported by domestic sales of ₹30,275 million and international sales of ₹14,540 million. However, net profit after non-controlling interest declined 11.7% year-on-year to ₹6,753 million, largely impacted by a higher effective tax rate and increased operating costs from the Enzene CDMO business and the integration of Occlutech.
10.00 lakh shares traded by 12 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.06 lakh shares (9.44 times). The five-day average daily volume was 1.05 lakh shares. Separately, the NSE report for 12 November 2026 showed 2.67 lakh shares delivered, representing 26.66% of that day’s traded volume. The same report recorded 88,996 trades.
The stock declined 2.68% amid heavy volume following the release of Q2 FY27 financial results, which showed strong top-line revenue growth accompanied by an 11.7% decline in net profit due to higher tax provisions and operating expenses.
Latest Company Developments
Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named 'Alkem Pharma Company' as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.
Expands Alkem's operational footprint and market reach into the Middle Eastern pharmaceutical sector.
Intimation of incorporation of subsidiary in the form of Joint Venture.
a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.
The filing reported 29 MF/UTI holders.
Research & Brokerage Views
Maintained a Neutral rating following earlier earnings performance while adjusting the target price to reflect valuation parameters and ongoing execution dynamics.
Historical Bulk / Block Deals
What to Watch Next
- Post-earnings analyst commentary and management guidance on operating margins and tax rates.
- Remediation progress and follow-up updates regarding the Daman formulations facility regulatory status.
- Execution and scaling of the newly incorporated Saudi Arabian joint venture subsidiary.
- Performance trends in international markets and integration milestones for Occlutech.
Other Dated Coverage
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026 — 23 October 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.03% | 22 October 2026 — 22 October 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026 — 14 October 2026
More Alkem Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Alkem Laboratories company news?
Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named 'Alkem Pharma Company' as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.
How strong was Alkem Laboratories’s trading volume?
10.00 lakh shares traded, 9.44 times the 20-day average daily volume. The price and volume data are dated 12 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.